Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel

23 February 2021


Fabio Augusto Barros Schutz, Ekaphop Sirachainan, Shanggar Kuppusamy, Nguyen Thi Thai Hoa, Thitiya Dejthevaporn, Badrulhisham Bahadzor, Vu Quang Toan, Phichai Chansriwong, Adlinda Alip, Nguyen Thi Minh Hue, Napa Parinyanitikul, Ai Lian Tan, Vu Dinh Khanh Hoang, Piyawan Tienchaiananda, Sai Naga Deepak Chinchapattanam, and Amit Garg

DOWNLOAD FULL PDF VIEW RESEARCH HERE
COPY CITATION
Copied!

Abstract

Aims:

Clinical decision making is challenging in men with metastatic prostate cancer (mPC), as heterogeneity in treatment options and patient characteristics have resulted in multiple scenarios with little or no evidence. The South East Asia Expert Panel 2019 addressed some of these challenges.

Methods:

Based on evidence in the literature and expert interviews, 19 statements were formulated for key challenges in the treatment of men with castration-sensitive and -resistant prostate cancer in clinical practice. A modified Delphi process was used to reach consensus among experts in the panel and develop clinical practice recommendations.

Results:

The majority of the panel preferred a risk-based stratification and recommended abiraterone or enzalutamide as first-line therapy for symptomatic chemotherapy naïve patients. Abiraterone is preferred over enzalutamide as a first-line treatment in these patients. However, the panel did not support the use of abiraterone in high risk lymph-node positive only (N+M0) or in non-metastatic (N0M0) patients. In select patients, low dose abiraterone with food may be used to optimize clinical outcomes. Androgen receptor gene splice variant status may be a useful guide to therapy. In addition, generic versions of approved therapies may improve access to treatment to a broader patient population. The choice of treatment, as well as sequencing are guided by both patient and disease characteristics, preferences, drug access, cost, and compliance.

Conclusion:

Expert recommendations are key to guidance for the optimal management of mPC. Appropriate choice, timing, and sequence of treatment options can help to tailor therapy to maximize outcomes in men with mPC.

Reference

  1. Ogden SR, Culp WC Jr, Villamaria FJ, et al. Developing a checklist: consensus via a modified Delphi technique. J Cardiothorac Vasc Anesth. 2016;30:855–858.
  2. Copeland C, Fisher J, Teodorczuk A. Development of an international undergraduate curriculum for delirium using a modified Delphi process. Age Ageing. 2018;47:131–137.
  3. Powell C. The Delphi technique: myths and realities. J Adv Nurs. 2003;41:376–382.
  4. Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012;143:336–346.
  5. Wood L, Black P, Heng D, et al. Using the Delphi technique to improve clinical outcomes through the development of quality indicators in renal cell carcinoma. J Oncol Pract. 2013;9:262–267.
  6. Meshkat B, Cowman S, Gethin G, et al. Using an e-Delphi technique in achieving consensus across disciplines for developing best practice in day surgery in Ireland. J Hosp Adm. 2014;3:1–8.
  7. Murphy MK, Black NA, Lamping DL, et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess. 1998;2:i–iv, 1–88.
  8. Butterwick DJ, Paskevich DM, Lagumen NG, et al. Development of content-valid technical skill assessment instruments for athletic taping skills. J Allied Health. 2006;35:147–155.
  9. Graefe A, Armstrong JS. Comparing face-to-face meetings, nominal groups, Delphi and prediction markets on an estimation task. Int J Forecasting. 2016;27:183–195.
  10. Gustafson DH, Shukla RK, Delbecq A, et al. A comparative study of differences in subjective likelihood estimates made by individuals, interacting groups, Delphi groups, and nominal groups. Organ Behav Hum Perform. 1973;9:280–291.
  11. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol. 1941;167:948–951.
  12. Harris WP, Mostaghel EA, Nelson PS, et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6:76–85.
  13. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737–746.
  14. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer. Lancet. 2016;387:1163–1177.
  15. Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–360.
  16. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338–351.
  17. Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer. Lancet Oncol. 2013;14:149–158.
  18. Egevad L, Granfors T, Karlberg L, et al. Prognostic value of the Gleason score in prostate cancer. BJU Int. 2002;89:538–542.
  19. James ND, Sydes MR, Clarke NW, et al. Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE). BJU Int. 2009;103:464–469.
  20. Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2018;36:1080–1087.
  21. Chiong E, Murphy DG, Akaza H, et al. Management of patients with advanced prostate cancer in the Asia Pacific region. BJU Int. 2019;123:22–34.
  22. Gravis G, Boher JM, Joly F, et al. ADT plus docetaxel versus ADT alone in metastatic prostate cancer. Eur Urol. 2016;70:256–262.
  23. Feyerabend S, Saad F, Li T, et al. Abiraterone plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer. Eur J Cancer. 2018;103:78–87.
  24. Clarke NW, Ali A, Ingleby FC, et al. Addition of docetaxel to hormonal therapy in metastatic hormone-sensitive prostate cancer. Ann Oncol. 2019;30:1992–2003.
  25. Ritch C, Cookson M. Recent trends in the management of advanced prostate cancer. F1000Res. 2018;7:1513.
  26. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–148.
  27. Ye D, Huang Y, Zhou F, et al. Phase 3 study of abiraterone acetate in mCRPC. Asian J Urol. 2017;4:75–85.
  28. Goodman OB Jr, Fraig TW, Molina A, et al. Visceral disease subgroup analysis in mCRPC. Prostate Cancer Prostatic Dis. 2014;17:34e9.
  29. Lojanapiwat B, Pripatnanont C, Choonhaklai V, et al. Management of mCRPC in Thailand. Prostate Int. 2017;5:1–7.
  30. Gillessen S, Attard G, Beer TM, et al. Advanced prostate cancer consensus conference report. Eur Urol. 2018;73:178–211.
  31. McNamara MA, George DJ, Ramaswamy K, et al. Survival by race in mCRPC treated with abiraterone or enzalutamide. J Clin Oncol. 2019;37:212.
  32. Thiery-Vuillemin A, et al. AQUARiUS study results. ASCO Annual Meeting. 2018.
  33. Shore ND, et al. REAAcT study results. ASCO GU Symposium. 2018.
  34. James ND, et al. Abiraterone in high-risk non-metastatic prostate cancer. Ann Oncol. 2018;28(Suppl 5):mdx440.027.
  35. Ryan CJ, Crawford ED, Shore ND, et al. IMAAGEN study. J Urol. 2018;200:344–352.
  36. Mohler JL, et al. NCCN prostate cancer guidelines v2.2019. J Natl Compr Canc Netw. 2019;17:479–505.
  37. Malangone-Monaco E, et al. Oral antineoplastic therapy prescribing patterns. Clin Ther. 2016;38:1817–1824.
  38. Stuyckens K, Saad F, Xu XS, et al. Population pharmacokinetics of abiraterone. Clin Pharmacokinet. 2014;53:1149–1160.
  39. FDA Center for Drug Evaluation and Research. Application 202379Orig1s000. 2011.
  40. Szmulewitz RZ, et al. Low-dose abiraterone with food vs standard dose. J Clin Oncol. 2018;36:1389–1395.
  41. Kolesar JM, Liu GX. Low-fat abiraterone food effect. J Clin Oncol. 2018;36:1385–1387.
  42. Nadiminty N, et al. NF-κB2/p52 induces enzalutamide resistance. Mol Cancer Ther. 2013;12:1629–1637.
  43. Sepe P, et al. AR-V7 detection in mCRPC. Cancers. 2019;11:E980.
  44. Armstrong AJ, et al. PROPHECY study. J Clin Oncol. 2019;37:1120–1129.
  45. Bastos DA, Antonarakis ES. AR-V7 and treatment selection. Precis Cancer Med. 2018;1:13.
  46. Castellan P, et al. Abiraterone acetate in early metastatic prostate cancer. Ther Clin Risk Manag. 2018;14:2341–2347.
  47. Hahn AW, et al. Metastatic castration-sensitive prostate cancer. ASCO Educ Book. 2018;38:363–371.
  48. Wang C, et al. Pharmacokinetics of generic vs branded abiraterone. Cancer Chemother Pharmacol. 2019;83:509–517.
  49. Aggarwal R. Abiraterone or docetaxel plus ADT in hormone-sensitive prostate cancer. Eur Urol. 2018;73:845–846.
  50. Sydes MR, et al. STAMPEDE multi-arm trial results. Ann Oncol. 2018;29:1235–1248.
  51. Wallis CJD, et al. Network meta-analysis of abiraterone vs docetaxel. Eur Urol. 2018;73:834–844.
  52. Vale CL, et al. STOPCAP systematic review. Ann Oncol. 2018;29:1249–1257.
  53. Xu L, Pachynski RK. Management of metastatic prostate cancer. Curr Urol Rep. 2018;19:79.
  54. Davis ID, et al. Enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381:121–131.
  55. Chi KN, et al. Apalutamide in metastatic castration-sensitive prostate cancer. N Engl J Med. 2019;381:13–24.
  56. Smith MR, et al. ARASENS trial. J Clin Oncol. 2018;36(Suppl 6):TPS383.
  57. Fitzpatrick JM, et al. Expert consensus on mCRPC management. Eur J Cancer. 2014;50:1617–1627.
  58. Fizazi K, et al. COU-AA-301 trial final OS analysis. Lancet Oncol. 2012;13:983–992.
  59. Scher HI, et al. Enzalutamide after chemotherapy. N Engl J Med. 2012;367:1187–1197.
  60. Noonan KL, et al. Abiraterone after enzalutamide progression. Ann Oncol. 2013;24:1802–1807.
  61. Matsubara N, et al. Sequence of abiraterone and enzalutamide. Clin Genitourin Cancer. 2018;16:142–148.
  62. Fenioux C, et al. Steroid switch in mCRPC. BJU Int. 2019;123:300–306.
  63. Romero-Laorden N, et al. Prednisone to dexamethasone switch study. Br J Cancer. 2018;119:1052–1059.
  64. Lorente D, et al. Steroid switch after abiraterone progression. Br J Cancer. 2014;111:2248–2253.

Cite

Schutz FAB, Sirachainan E, Kuppusamy S, et al. Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel. Therapeutic Advances in Medical Oncology. 2021;13. doi:10.1177/1758835920985464

COPY CITATION Copied!
DOWNLOAD FULL PDF VIEW RESEARCH HERE